HOME >> BIOLOGY >> NEWS
Abgenix reports positive clinical data with ABX-IL8 in Psoriasis

Improvement Seen with Multiple Parameters of Disease Measurement

FREMONT, Calif., November 30, 1999 - Abgenix, Inc. (Nasdaq: ABGX) today reported top level results of its Phase I/II clinical trial with ABX-IL8, a fully human antibody developed with the company's XenoMouse™ technology. Additional details will be presented at the Psoriasis: from Gene to Clinic meeting in London on December 2,1999. The multi-center, placebo controlled trial involved 45 patients with moderate to severe psoriasis. Abgenix reported that ABX-IL8 was safe and well tolerated at all dose levels tested and that a dose-dependent improvement was seen in multiple measures of disease. These efficacy measures included psoriasis area severity index (PASI), total body surface area (BSA), Physician's Global Assessment (PGA), and plaque photographs. The company also indicated that it plans to initiate a Phase II clinical trial in psoriasis during the first half of 2000. Other inflammatory disease indications including rheumatoid arthritis continue to be evaluated.

PASI analysis is a widely accepted measure of drug response in psoriasis patients. Fifty-eight percent (58%) of the patients who received ABX-IL8 1.0 mg/kg and 3.0 mg/kg, administered once every three weeks for four consecutive doses, achieved a >25% improvement, and 21% of patients achieved a >50% improvement in PASI score. This compared favorably to patients receiving 0.3 mg/kg ABX-IL8 (20% of patients achieved a >25% improvement and 0% a >50% improvement) and to patients receiving placebo (0% of patients with improvement of >25%). BSA and PGA measures and plaque photographs also showed dose dependent improvement.

"The Phase I/II trial of ABX-IL8 was primarily designed to demonstrate safety so it is a nice surprise to see such encouraging results on efficacy parameters," stated R. Scott Greer, president and CEO of Abgenix. "We will be optimizing the dose and regimen of ABX-IL8
'"/>

Contact: Kurt Leutzinger, Abgenix
510-608-6575
Porter Novelli
30-Nov-1999


Page: 1 2 3

Related biology news :

1. Abgenix to become sole owner of Xenomouse fully human antibody technology
2. Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs
3. Abgenix initiates phase III clinical trial of graft versus host disease therapy
4. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
5. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune disease and cancer
6. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
7. APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
8. Scientists question reports of massive ant supercolonies in California and Europe
9. Survey reports fall in stem cell transplants for breast cancer
10. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
11. Immerge reports PERVs most infectious to human cells not part of germ-line DNA of mini-swine

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Abgenix reports positive clinical data with ABX Psoriasis

(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... edge technologies including Wocket™, the Smart Wallet, at the ... FiRe is a leading global conference on the intersection ... by Mark Anderson , founder and publisher of ...
(Date:10/15/2014)... has admitted Johannes Gutenberg University Mainz (JGU) as ... hub continues to maintain a significant nationwide standing ... "The acceptance of Johannes Gutenberg University Mainz as ... milestone in the national and international competition for ... of Rhineland-Palatinate can be proud that Mainz University ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
(Date:10/25/2014)... , October 24, 2014 Investor-Edge ... (NASDAQ: CYTR ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... on these five companies can be accessed at: ... October 23, 2014, ended on a positive note as ...
(Date:10/25/2014)... , October 24, 2014 ... Markets ( http://www.researchandmarkets.com/research/t5t5pd/the_global_market ) has announced the addition ... Nanotubes, Graphene And Other 2-D Nanomaterials " ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,CNTs and graphene are ... known to man, with a performance-per-weight greater ...
(Date:10/22/2014)... , Oct. 22, 2014 Research ... the "Global DNA Diagnostics Market (Product types, ... Share, Global Trends, Company Profiles, Demand, Insights, Analysis, ... 2020" report to their offering. ... (products, applications, techniques, end users and Geography) Global ...
(Date:10/22/2014)... The Americas Inorganic Refrigerants Market report ... Americas with analysis and forecast of revenue. , ... Refrigerants Market report, to get an idea of ... glimpse of the segmentation in the Americas inorganic ... and figures. , http://www.micromarketmonitor.com/market/americas-inorganic-refrigerants-4191654241.html , ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3
Cached News: